US · Healthcare · Biotechnology
EPS came in at 0.03 against a street estimate of -11.50 — a beat of 100.3%.
Analysts rate Lakefront Biotherapeutics NV a hold (2 buy, 3 hold, 1 sell out of 6) with an average price target of $30.33.
| Fund | Stake |
|---|---|
| TANG CAPITAL MANAGEMENT LLC | 5.77% |
| Madison Avenue Partners, LP | 5.25% |
| Prosight Management, LP | 3.11% |
| EcoR1 Capital, LLC | 2.54% |
| Ameriprise Financial Inc | 1.94% |
| Renaissance Technologies Corp | 0.62% |
| BlackRock Inc | 0.52% |
| Point72 Asset Management, L.P. | 0.41% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • The filing is a Form 6-K submitted by Lakefront Biotherapeutics for November 2026. • The company issued the related press release | 2026-11-04 |
| Current report (6-K) · Q4 2026 OTHER NOTABLE POINTS • Lakefront Biotherapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission for November 2026. • The filing s | 2026-11-02 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 107,804 ordinary shares between October 12, 2026, and October 16, 2026. • The shares were b | 2026-10-20 |
| Current report (6-K) · Q4 2026 OTHER NOTABLE POINTS • Lakefront Biotherapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission for October 2026. • The filing wa | 2026-10-15 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 126,322 ordinary shares between October 05, 2026 and October 09, 2026. • The shares were bo | 2026-10-13 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Bank of America Corporation’s combined Lakefront Biotherapeutics voting rights and equivalent financial instruments fell below the | 2026-10-09 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 117,437 ordinary shares between September 28, 2026 and October 02, 2026. • The shares were | 2026-10-06 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 106,060 ordinary shares between September 21, 2026, and September 25, 2026, under its repurc | 2026-09-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lakefront Biotherapeutics NV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.